FFR-Guided CABG Improves Outcomes in Valve Surgery Patients with CAD

For patients undergoing valve surgery alongside treatment for coronary artery disease, a more precise approach to bypass grafting—one guided by physiological assessment rather than standard angiography—appears to improve outcomes. Recent findings from the FAVOR IV-QVAS trial, a multicentre, triple-blind, randomised study conducted in China, suggest that using angiography-derived fractional flow reserve (Angio-FFR) to determine which arteries need bypasses reduces the risk of complications compared to relying solely on anatomical assessments from angiography.

Understanding the Challenge: Valve Surgery and Coronary Artery Disease

Many patients requiring valve surgery also have underlying coronary artery disease (CAD), where arteries develop into narrowed, reducing blood flow to the heart. Traditionally, surgeons have used coronary angiography – an X-ray imaging technique – to identify these narrowed arteries and determine where to perform coronary artery bypass grafting (CABG), a procedure that reroutes blood flow around blockages. However, angiography only shows the anatomy of the arteries, not how significantly a narrowing is actually impacting blood flow. This represents where fractional flow reserve (FFR) comes in.

FFR measures the pressure difference across a narrowing in an artery, providing a physiological assessment of its impact on blood flow. Angio-FFR builds on this by deriving FFR information directly from angiography images, streamlining the process. The FAVOR IV-QVAS trial investigated whether guiding CABG with Angio-FFR, rather than relying solely on angiography, would lead to better outcomes for these patients. The study, published in The Lancet, enrolled nearly 800 patients undergoing valve surgery with concomitant CAD, randomly assigning them to either an Angio-FFR-guided strategy or a conventional angiography-guided strategy.

FAVOR IV-QVAS: Trial Design and Key Findings

The FAVOR IV-QVAS trial (NCT03977129) was designed to be rigorous. An independent panel of surgeons created two CABG plans for each patient based on both angiography and Angio-FFR data. Patients were then randomly assigned to have surgery based on either the Angio-FFR-derived plan or the angiography-derived plan, with the surgeons blinded to the assigned strategy. The primary endpoint was a composite of perioperative outcomes, including death, stroke, myocardial infarction (heart attack), or repeat revascularisation.

The results showed that the physiologically guided CABG, using Angio-FFR, reduced the incidence of this composite outcome compared to the anatomically guided approach. As reported by Cardiology Now News, this provides strong evidence that assessing blood flow physiologically, in addition to looking at the anatomy of the arteries, can improve outcomes in this specific patient population. This suggests that a more selective approach to surgical coronary revascularisation, guided by physiological assessment, is beneficial for patients undergoing valve procedures.

What Does FFR Actually Measure? A Plain-English Explanation

Imagine a garden hose with a kink in it. The kink restricts water flow, even though the hose itself isn’t completely blocked. Angiography is like looking at the kink – you can spot it’s there, but you don’t necessarily know how much it’s restricting the water flow. FFR, measures the pressure before and after the kink to determine how significantly it’s impacting the overall flow. In the context of coronary arteries, FFR helps doctors understand whether a narrowing is truly causing a significant reduction in blood supply to the heart muscle.

Evidence and Limitations: Interpreting the Results

It’s important to note that the FAVOR IV-QVAS trial, while robust, has limitations. The study population was specific to patients undergoing valve surgery with concomitant CAD. The findings may not be directly applicable to patients with CAD alone, or those undergoing different types of cardiac surgery. The study was conducted in China, and results may vary in different populations due to genetic or lifestyle factors. A meta-analysis published in PMC highlights the growing body of evidence supporting FFR-guided CABG, but also underscores the need for further research to confirm these findings in diverse patient populations.

The trial also used Angio-FFR, a specific method for deriving FFR from angiography images. While convenient, Angio-FFR has its own potential limitations compared to traditional wire-based FFR measurements. The study’s triple-blind design – meaning that patients, surgeons, and outcome assessors were all unaware of the assigned treatment strategy – helps to minimize bias, but doesn’t eliminate the possibility of subtle differences in surgical technique or post-operative care that could influence outcomes.

What Does This Mean for Patients?

These findings don’t mean that all patients with CAD undergoing valve surgery should automatically receive Angio-FFR-guided CABG. Rather, they support a more nuanced approach to treatment decisions. The trial suggests that for patients with significant CAD identified during valve surgery evaluation, a physiological assessment like Angio-FFR can help identify which arteries truly need to be bypassed, potentially avoiding unnecessary procedures and improving overall outcomes. Patients should discuss their individual risk factors and treatment options with a qualified cardiologist or cardiac surgeon to determine the best course of action.

The Evolving Landscape of Coronary Revascularisation

The FAVOR IV-QVAS trial contributes to a growing body of evidence supporting the use of physiological assessment in guiding coronary revascularisation. This represents a shift away from a purely anatomical approach, towards a more personalized strategy that considers the functional significance of coronary artery narrowings. This approach isn’t limited to CABG; FFR is also used to guide percutaneous coronary intervention (PCI), a less invasive procedure involving the placement of stents to open blocked arteries.

What Comes Next: Surveillance and Guidance Updates

The results of the FAVOR IV-QVAS trial are likely to be considered by professional societies and guideline committees as they update recommendations for the management of CAD in patients undergoing valve surgery. Ongoing surveillance of outcomes following Angio-FFR-guided CABG will be important to confirm the long-term benefits and identify any potential risks. Further research is also needed to compare Angio-FFR to other physiological assessment techniques, and to determine the optimal strategy for guiding coronary revascularisation in different patient subgroups. Clinicians will continue to evaluate individual patient cases, weighing the benefits and risks of different approaches based on the latest evidence and clinical judgment.